Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2025-01-02 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Next Day Disclosure Return filed under the Hong Kong Stock Exchange Listing Rules, detailing changes in issued and treasury shares and a repurchase report (on-market share buybacks). It is not an earnings release, management change, or financing update, but rather a report of the company’s transaction in its own shares (share repurchase). This matches the ‘Transaction in Own Shares’ category.
2025-01-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 92% confidence The document is a Hong Kong Stock Exchange FF305 “Next Day Disclosure Return” detailing changes in issued shares (treasury) and, critically, Section II outlines the company’s share repurchase on-market (repurchases for cancellation and treasury shares). This is a statutory disclosure of the company’s transactions in its own shares rather than an annual or interim report, governance statement, or financing update. Therefore, it matches ‘Transaction in Own Shares’ (POS).
2024-12-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 91% confidence The document is a completed ‘Next Day Disclosure Return’ (Form FF305) under Hong Kong Main Board Rule 13.25A/GEM Rule 17.27A for changes in issued shares and detailed repurchase transactions. It is not an earnings release, annual report, or management discussion; rather it specifically reports on the company’s own share repurchases and treasury share movements. This fits the ‘Transaction in Own Shares’ category (Code: POS).
2024-12-26 English
RENEWAL OF CONTINUING CONNECTED TRANSACTIONS
Regulatory Filings Classification · 95% confidence The document is a Hong Kong Stock Exchange announcement regarding the renewal of continuing connected transactions under Listing Rule Chapter 14A. It outlines framework agreements, related party relationships, pricing policies, historical transaction amounts and proposed annual caps—all typical of a regulatory announcement rather than a financial report (e.g., not an annual/quarterly report, earnings release or management discussion). There is no mention of share issues, dividends, proxy materials or legal proceedings. It is a compliance announcement under the Listing Rules, best fitting the “Regulatory Filings” (RNS) category.
2024-12-23 English
FURTHER CHANGE IN USE OF PROCEEDS
Capital/Financing Update Classification · 90% confidence The document is an announcement by Simcere Pharmaceutical Group regarding a ‘‘Further Change in Use of Proceeds’’ from its global offering. It details the reallocation of unutilized net proceeds previously raised, provides updated tables of utilization, and explains the rationale for reassigning capital to new R&D projects. There are no financial statements like an interim report or 10-K, nor board or dividend items. This is clearly a financing update on capital usage following a share offering, fitting the Capital/Financing Update category.
2024-12-23 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Regulatory Filings Classification · 84% confidence The document is a standardized monthly return (HKEX Form FF301) filed with the Hong Kong Stock Exchange, detailing movements in the issuer’s share capital and treasury shares for the month. It is not an earnings or financial report, nor an annual or interim report; rather, it is a regulatory compliance filing under the Exchange Listing Rules. This does not match any specialized category such as share issue announcement (which would focus only on new issues) or management discussion. Therefore, it best fits the fallback “Regulatory Filings” category (RNS).
2024-12-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.